ResMed announced the SERVE-HF study at the 18th European Respiratory Society Annual Congress in Berlin, Germany on the market. The study the use of its the use of their AutoSet CS 2 device in the treatment of sleep-disordered breathing that affects patients with chronic heart failure follow this web-site .
Effective treatment of respiratory problems, such as sleep-disordered breathing is important to ensure that patients and healthy sleep is not interrupted. Also disappear the typical symptoms such as fatigue and daytime sleepiness and also a significant improvement in patients quality of life.
The results were consistent and sturdy in many study designs;. Studies which recorded were needed to the patient to follow on at least 1 year Kirtane observed that knowledge should help to calm down patient and physician on the safety DES in the off-label use.